Elsayed Ammar A, Hussein Abbas F A, Saad Yousef H, Elbabry Khaled, Elhalag Rowan H, Eissa Fadi, Nasr Ahmed, Khaled Abdellate, Chavda Vishal, Khan Mohammad M, Chaurasia Bipin
Faculty of Medicine, Benha University, Benha, Egypt.
Department of Neurosurgery, College of Medicine, University of Babylon, Babylon, Iraq.
J Neurol Surg Rep. 2025 Jul 12;86(3):e140-e148. doi: 10.1055/a-2642-8152. eCollection 2025 Jul.
Recent studies show potential benefits of albendazole in managing cisternal neurocysticercosis (NCC), which reduces parasitic burden. This systematic review and meta-analysis aim to evaluate the efficacy of albendazole and other pharmacological treatments in cisternal NCC, considering the heterogeneity of disease manifestations and the need for effective treatment strategies.
Comprehensive searches were conducted across PubMed, Web of Science, Scopus, CENTRAL, and Embase up to March 2024, focusing on RCTs and observational studies that examined albendazole's impact on cisternal NCC. Data were pooled using a random-effects model, adhering to the Cochrane handbook for systematic reviews and meta-analysis and the preferred reporting items for systematic reviews and meta-analyses guidelines, to calculate relative risks (RRs) for various outcomes, including cyst resolution and side effects.
Eight studies with 2,001 patients treated with albendazole, comparing outcomes against placebo or no treatment. Findings indicated a statistically significant decrease in complete cyst resolution among albendazole recipients (RR = 0.69), with notable heterogeneity across studies. No significant differences were observed in persistent cysts, partial cyst resolution, seizures, nonneurological side effects, death, or calcification rates posttreatment. Adjustments for heterogeneity refined some associations, particularly with persistent cysts after excluding specific studies.
Albendazole demonstrates potential in reducing active cysts in cisternal NCC, though its efficacy varies across different clinical outcomes, necessitating personalized treatment approaches. The observed heterogeneity and the variable impact on cyst resolution and seizures underscore the complexity of managing NCC. Further high-quality, large-scale RCTs are essential to solidify these findings and guide treatment protocols, emphasizing the need for multidisciplinary strategies in addressing this challenging condition.
近期研究表明,阿苯达唑在治疗脑池型神经囊尾蚴病(NCC)方面具有潜在益处,可减轻寄生虫负荷。本系统评价和荟萃分析旨在评估阿苯达唑及其他药物治疗脑池型NCC的疗效,同时考虑疾病表现的异质性以及有效治疗策略的需求。
截至2024年3月,在PubMed、科学网、Scopus、CENTRAL和Embase数据库中进行了全面检索,重点关注研究阿苯达唑对脑池型NCC影响的随机对照试验(RCT)和观察性研究。数据采用随机效应模型进行汇总,遵循Cochrane系统评价和荟萃分析手册以及系统评价和荟萃分析的首选报告项目指南,计算包括囊肿消退和副作用在内的各种结局的相对风险(RR)。
八项研究共纳入2001例接受阿苯达唑治疗的患者,将其结局与安慰剂或未治疗组进行比较。结果表明,接受阿苯达唑治疗的患者完全囊肿消退率在统计学上显著降低(RR = 0.69),各研究间存在显著异质性。治疗后在持续囊肿、部分囊肿消退、癫痫发作、非神经副作用、死亡或钙化率方面未观察到显著差异。对异质性进行调整后,一些关联得到了优化,特别是在排除特定研究后与持续囊肿的关联。
阿苯达唑在减少脑池型NCC中的活动性囊肿方面显示出潜力,但其疗效因不同临床结局而异,因此需要个性化治疗方法。观察到的异质性以及对囊肿消退和癫痫发作的可变影响凸显了管理NCC的复杂性。进一步开展高质量、大规模的RCT对于巩固这些发现并指导治疗方案至关重要,强调了在应对这一具有挑战性的疾病时采用多学科策略的必要性。